Clinical Trial Update: Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating hydroxychloroquine as a steroid-sparing treatment for extrapulmonary sarcoidosis, including pulmonary involvement, currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Sarcoidosis
• Sarcoidosis

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Sarcoidosis, Pulmonary | Phase 4 | Status: RECRUITING